Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Impedimed Limited ( (AU:IPD) ) has shared an update.
Impedimed Limited’s 2025 Annual General Meeting highlighted significant achievements, including a 23% revenue growth and increased payor coverage in 26 states, which is expected to boost BCRL sales. The company is strategically investing in sales capabilities and refining processes to enhance SOZO device utilization. The SOZO digital health platform, with FDA-cleared applications, presents substantial opportunities in heart failure and body composition markets, valued at $1.1 billion and $600 million respectively. The board supports exploring collaborations and acquisitions to maximize the platform’s value, while cost resizing efforts aim to secure future success.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited operates in the healthcare industry, focusing on the diagnosis and management of lymphoedema. The company is known for its SOZO device, which aids in workflow management for surgeons and clinicians. Impedimed is also involved in cardiac health, wellness, and medical weight management, with a strong emphasis on digital health platforms.
Average Trading Volume: 1,744,826
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$79.46M
See more insights into IPD stock on TipRanks’ Stock Analysis page.